CN Patent

CN114144232A — N-[4-(氯二氟甲氧基)苯基]-6-[(3r)-3-羟基吡咯烷-1-基]-5-(1h-吡唑-5-基)吡啶-3-甲酰胺的结晶形式

Assigned to Novartis AG · Expires 2022-03-04 · 4y expired

What this patent protects

本发明描述了N‑[4‑(氯二氟甲氧基)苯基]‑6‑[(3R)‑3‑羟基吡咯烷‑1‑基]‑5‑(1H‑吡唑‑5‑基)吡啶‑3‑甲酰胺的具体结晶形式。本发明进一步涉及用于制备所述结晶形式的方法、包含所述结晶形式的药物组合物、以及使用所述结晶形式和药物组合物治疗疾病的方法。

USPTO Abstract

本发明描述了N‑[4‑(氯二氟甲氧基)苯基]‑6‑[(3R)‑3‑羟基吡咯烷‑1‑基]‑5‑(1H‑吡唑‑5‑基)吡啶‑3‑甲酰胺的具体结晶形式。本发明进一步涉及用于制备所述结晶形式的方法、包含所述结晶形式的药物组合物、以及使用所述结晶形式和药物组合物治疗疾病的方法。

Drugs covered by this patent

Patent Metadata

Patent number
CN114144232A
Jurisdiction
CN
Classification
—
Expires
2022-03-04
Drug substance claim
No
Drug product claim
No
Assignee
Novartis AG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.